30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Perspective Therapeutics Inc (CATX)

Track

Stock chart
Ticker: CATX Exchange: ASE
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Hunt Jonathan Robert
Chief Accounting Officer
1 purchase — total 22,295 USD
Buy 13 Nov 2025
Value US$778,717.93 | Price 110.02 | Shares 93,127
Buy 12 Nov 2025
Value US$1,246,101.65 | Price 454.96 | Shares 41,085
Buy 31 Mar 2025
Value US$81,775.25 | Price 2.14 | Shares 38,145
Buy 31 Mar 2025
Value US$49,999.40 | Price 2.13 | Shares 23,475
Buy 28 Mar 2025
Value US$10,288.12 | Price 2.21 | Shares 4,650
Buy 28 Mar 2025
Value US$49,384.49 | Price 2.24 | Shares 22,026
Buy 28 Mar 2025
Value US$50,375.84 | Price 2.27 | Shares 22,192
Buy 28 Mar 2025
Value US$74,945.92 | Price 2.25 | Shares 33,333
Buy 4 Dec 2024
Value US$100,003.75 | Price 3.85 | Shares 25,975
Buy 4 Dec 2024
Value US$30,132.00 | Price 3.77 | Shares 8,000
Buy 25 Nov 2024
Value US$9,611.73 | Price 3.67 | Shares 2,619
Buy 25 Nov 2024
Value US$13,201.78 | Price 3.62 | Shares 3,647
Buy 25 Nov 2024
Value US$38,800.00 | Price 3.88 | Shares 10,000
Buy 25 Nov 2024
Value US$8,640.00 | Price 3.60 | Shares 2,400
Buy 25 Nov 2024
Value US$114.26 | Price 3.94 | Shares 29
Buy 25 Nov 2024
Value US$1,420.00 | Price 3.55 | Shares 400
Buy 25 Nov 2024
Value US$25,080.00 | Price 3.80 | Shares 6,600
Buy 25 Nov 2024
Value US$20,520.00 | Price 3.80 | Shares 5,400
Buy 25 Nov 2024
Value US$54,868.00 | Price 3.78 | Shares 14,500
Proposed sale 12 Sep 2024
Value US$39,500.00 | Price 15.80 | Shares 2,500
Buy 17 Jun 2024
Value US$17,667.00 | Price 9.82 | Shares 1,800
Buy 14 Jun 2024
Value US$896.40 | Price 10.80 | Shares 83
Buy 14 Jun 2024
Value US$49,093.60 | Price 10.90 | Shares 4,504
Buy 13 Jun 2024
Value US$117,430.00 | Price 1.17 | Shares 100,000
Buy 3 Jun 2024
Value US$49,992.31 | Price 1.46 | Shares 34,246
Buy 31 May 2024
Value US$75,900.00 | Price 1.38 | Shares 55,000
Buy 31 May 2024
Value US$16,800.00 | Price 1.40 | Shares 12,000
Buy 31 May 2024
Value US$18,207.10 | Price 1.40 | Shares 13,006
Buy 29 May 2024
Value US$24,999.04 | Price 1.34 | Shares 18,656
Buy 29 May 2024
Value US$15,015.00 | Price 1.32 | Shares 11,375
Buy 6 Mar 2024
Value US$57,409,487.05 | Price 0.95 | Shares 60,431,039
Buy 30 Jan 2024
Value US$2,450.00 | Price 0.70 | Shares 3,500
Buy 30 Jan 2024
Value US$30,872.88 | Price 0.72 | Shares 42,879
Buy 30 Jan 2024
Value US$40,555.91 | Price 0.71 | Shares 57,121
Buy 30 Jan 2024
Value US$3,640.17 | Price 0.71 | Shares 5,127
Buy 30 Jan 2024
Value US$13,191.09 | Price 0.71 | Shares 18,579
Buy 29 Jan 2024
Value US$13,590.40 | Price 0.64 | Shares 21,235
Buy 29 Jan 2024
Value US$2,579.84 | Price 0.64 | Shares 4,031
Buy 26 Jan 2024
Value US$27,000.00 | Price 0.54 | Shares 50,000
Buy 26 Jan 2024
Value US$13,750.00 | Price 0.55 | Shares 25,000
Buy 26 Jan 2024
Value US$5,022.67 | Price 0.59 | Shares 8,513
Buy 26 Jan 2024
Value US$9,058.50 | Price 0.61 | Shares 14,850
Buy 26 Jan 2024
Value US$7,472.50 | Price 0.61 | Shares 12,250
Buy 25 Jan 2024
Value US$10,845.66 | Price 0.49 | Shares 22,134
Buy 24 Jan 2024
Value US$139,888.00 | Price 0.50 | Shares 280,000
Buy 24 Jan 2024
Value US$14,632.38 | Price 0.49 | Shares 29,862
Buy 21 Dec 2023
Value US$1,202.56 | Price 0.33 | Shares 3,663
Buy 19 Dec 2023
Value US$137,000.00 | Price 0.34 | Shares 400,000
Buy 19 Dec 2023
Value US$4,377.60 | Price 0.32 | Shares 13,680
Buy 18 Dec 2023
Value US$15,461.22 | Price 0.26 | Shares 60,419
Buy 18 Dec 2023
Value US$2,600.00 | Price 0.26 | Shares 10,000
Buy 18 Dec 2023
Value US$32,337.50 | Price 0.26 | Shares 125,000
Buy 15 Dec 2023
Value US$36,276.11 | Price 0.27 | Shares 135,006
Buy 15 Dec 2023
Value US$41,284.44 | Price 0.27 | Shares 152,962
Buy 14 Dec 2023
Value US$8,704.26 | Price 0.27 | Shares 32,238
Buy 5 Dec 2022
Value US$12,236.00 | Price 0.38 | Shares 32,200
Buy 1 Dec 2022
Value US$20,265.40 | Price 0.38 | Shares 53,204
Buy 15 Nov 2022
Value US$33,540.00 | Price 0.34 | Shares 100,000
Buy 9 Jun 2022
Value US$3,959.22 | Price 0.29 | Shares 13,800
Buy 8 Jun 2022
Value US$1,425.00 | Price 0.29 | Shares 5,000
Buy 8 Jun 2022
Value US$7,443.18 | Price 0.29 | Shares 25,675
Buy 7 Jun 2022
Value US$22,230.00 | Price 0.30 | Shares 75,000
Buy 7 Jun 2022
Value US$3,717.68 | Price 0.28 | Shares 13,325
Buy 30 Nov 2020
Value US$25,534.00 | Price 0.38 | Shares 68,000
Buy 22 Oct 2020
Value US$34,999.12 | Price 0.52 | Shares 67,306
Buy 22 Oct 2020
Value US$9,999.60 | Price 0.52 | Shares 19,230
Buy 22 Oct 2020
Value US$24,999.52 | Price 0.52 | Shares 48,076
Buy 22 Oct 2020
Value US$3,999.84 | Price 0.52 | Shares 7,692
Buy 22 Oct 2020
Value US$9,999.60 | Price 0.52 | Shares 19,230
Buy 22 Oct 2020
Value US$9,999.60 | Price 0.52 | Shares 19,230
Buy 22 Oct 2020
Value US$10,400.00 | Price 0.52 | Shares 20,000
Buy 22 Oct 2020
Value US$14,998.88 | Price 0.52 | Shares 28,844
Buy 20 Nov 2019
Value US$19,495.00 | Price 0.39 | Shares 50,000
Buy 15 Nov 2019
Value US$3,900.00 | Price 0.39 | Shares 10,000
Buy 15 Nov 2019
Value US$9,745.00 | Price 0.39 | Shares 25,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-11-17 2025-11-13 B Purchase
3.8
Hunt Jonathan Robert

Chief Accounting Officer

Officer
93,127 -21.0%
110.02
US$778,718 		93,127 -21.0% 110.02 US$778,718
2025-11-14 2025-11-12 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
41,085 -27.5%
454.96
US$1,246,102 		41,085 -27.5% 454.96 US$1,246,102
2025-04-01 2025-03-31 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
73,820 -18.0%
434.72
US$62,705 		73,820 -18.0% 434.72 US$62,705
2025-04-01 2025-03-31 B Purchase
4.0
Woods Lori A
Non-Executive Director
23,475 +14.7%
2.13
US$49,999 		23,475 +14.7% 2.13 US$49,999
2025-04-01 2025-03-28 B Purchase
3.6
Spoor Johan M.

Chief Executive Officer

Executive Director
4,650 +inf%
2.21
US$10,288 		4,650 +inf% 2.21 US$10,288
2025-04-01 2025-03-28 B Purchase
3.6
Spoor Johan M.

Chief Executive Officer

Executive Director
22,026 +59.0%
2.24
US$49,384 		22,026 +59.0% 2.24 US$49,384
2025-04-01 2025-03-28 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
22,192 +45.6%
2.27
US$50,376 		22,192 +45.6% 2.27 US$50,376
2025-04-01 2025-03-28 B Purchase
3.9
Graham Juan

Chief Financial Officer

Officer
33,333 +1649.3%
2.25
US$74,946 		33,333 +1649.3% 2.25 US$74,946
2024-12-06 2024-12-04 B Purchase
0.6
HENSON HEIDI
Non-Executive Director
25,975 +inf%
3.85
US$100,004 		25,975 +inf% 3.85 US$100,004
2024-12-04 2024-12-04 B Purchase
3.6
Spoor Johan M.

CEO

Executive Director
8,000 +28.3%
3.77
US$30,132 		8,000 +28.3% 3.77 US$30,132
2024-11-27 2024-11-25 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
2,619 +0.6%
3.67
US$9,612 		2,619 +0.6% 3.67 US$9,612
2024-11-27 2024-11-25 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
3,647 +0.9%
3.62
US$13,202 		3,647 +0.9% 3.62 US$13,202
2024-11-27 2024-11-25 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
10,000 +25.8%
3.88
US$38,800 		10,000 +25.8% 3.88 US$38,800
2024-11-27 2024-11-25 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
2,400 +6.6%
3.60
US$8,640 		2,400 +6.6% 3.60 US$8,640
2024-11-27 2024-11-25 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
29 +0.1%
3.94
US$114 		29 +0.1% 3.94 US$114
2024-11-27 2024-11-25 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
400 +1.1%
3.55
US$1,420 		400 +1.1% 3.55 US$1,420
2024-11-26 2024-11-25 B Purchase
3.6
Spoor Johan M.

CEO

Executive Director
6,600 +11.0%
3.80
US$25,080 		6,600 +11.0% 3.80 US$25,080
2024-11-26 2024-11-25 B Purchase
3.6
Spoor Johan M.

CEO

Executive Director
5,400 +inf%
3.80
US$20,520 		5,400 +inf% 3.80 US$20,520
2024-11-26 2024-11-25 B Purchase
3.6
Spoor Johan M.

CEO

Executive Director
14,500 +10.5%
3.78
US$54,868 		14,500 +10.5% 3.78 US$54,868
2024-09-12 2024-09-12 PrS Proposed sale
3.5
Mark Austin

affiliate
2,500
15.80
US$39,500 		2,500 15.80 US$39,500
2024-06-18 2024-06-17 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
1,800 +5.3%
9.82
US$17,667 		1,800 +5.3% 9.82 US$17,667
2024-06-18 2024-06-14 B Purchase
4.0
Woods Lori A
Non-Executive Director
83 +0.1%
10.80
US$896 		83 +0.1% 10.80 US$896
2024-06-18 2024-06-14 B Purchase
4.0
Woods Lori A
Non-Executive Director
4,504 +2.9%
10.90
US$49,094 		4,504 +2.9% 10.90 US$49,094
2024-06-13 2024-06-13 B Purchase
3.6
Spoor Johan M.

CEO

Executive Director
100,000 +266.2%
1.17
US$117,430 		100,000 +266.2% 1.17 US$117,430
2024-06-04 2024-06-03 B Purchase
4.0
Woods Lori A
Non-Executive Director
34,246 +2.3%
1.46
US$49,992 		34,246 +2.3% 1.46 US$49,992
2024-06-03 2024-05-31 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
55,000 +14.9%
1.38
US$75,900 		55,000 +14.9% 1.38 US$75,900
2024-06-03 2024-05-31 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
12,000 +3.6%
1.40
US$16,800 		12,000 +3.6% 1.40 US$16,800
2024-06-03 2024-05-31 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
13,006 +4.1%
1.40
US$18,207 		13,006 +4.1% 1.40 US$18,207
2024-05-30 2024-05-29 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
18,656 +5.3%
1.34
US$24,999 		18,656 +5.3% 1.34 US$24,999
2024-05-30 2024-05-29 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
11,375 +3.4%
1.32
US$15,015 		11,375 +3.4% 1.32 US$15,015
2024-03-08 2024-03-06 B Purchase
Lantheus Alpha Therapy, LLC
Large shareholder
60,431,039 +107.3%
0.95
US$57,409,487 		60,431,039 +107.3% 0.95 US$57,409,487
2024-02-01 2024-01-30 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
3,500 +1.0%
0.70
US$2,450 		3,500 +1.0% 0.70 US$2,450
2024-02-01 2024-01-30 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
42,879 +14.7%
0.72
US$30,873 		42,879 +14.7% 0.72 US$30,873
2024-02-01 2024-01-30 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
57,121 +24.3%
0.71
US$40,556 		57,121 +24.3% 0.71 US$40,556
2024-02-01 2024-01-30 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
5,127 +2.2%
0.71
US$3,640 		5,127 +2.2% 0.71 US$3,640
2024-02-01 2024-01-30 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
18,579 +8.8%
0.71
US$13,191 		18,579 +8.8% 0.71 US$13,191
2024-01-30 2024-01-29 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
21,235 +11.2%
0.64
US$13,590 		21,235 +11.2% 0.64 US$13,590
2024-01-30 2024-01-29 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
4,031 +2.2%
0.64
US$2,580 		4,031 +2.2% 0.64 US$2,580
2024-01-30 2024-01-26 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
50,000 +36.7%
0.54
US$27,000 		50,000 +36.7% 0.54 US$27,000
2024-01-30 2024-01-26 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
25,000 +22.5%
0.55
US$13,750 		25,000 +22.5% 0.55 US$13,750
2024-01-30 2024-01-26 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
8,513 +8.3%
0.59
US$5,023 		8,513 +8.3% 0.59 US$5,023
2024-01-30 2024-01-26 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
14,850 +16.9%
0.61
US$9,058 		14,850 +16.9% 0.61 US$9,058
2024-01-30 2024-01-26 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
12,250 +16.2%
0.61
US$7,472 		12,250 +16.2% 0.61 US$7,472
2024-01-26 2024-01-25 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
22,134 +41.3%
0.49
US$10,846 		22,134 +41.3% 0.49 US$10,846
2024-01-26 2024-01-24 B Purchase
3.8
Puhlmann Markus

Chief Medical Officer

Officer
280,000 +25.6%
0.50
US$139,888 		280,000 +25.6% 0.50 US$139,888
2024-01-26 2024-01-24 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
29,862 +126.1%
0.49
US$14,632 		29,862 +126.1% 0.49 US$14,632
2023-12-26 2023-12-21 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
3,663 +inf%
0.33
US$1,203 		3,663 +inf% 0.33 US$1,203
2023-12-19 2023-12-19 B Purchase
3.8
Puhlmann Markus

Chief Medical Officer

Officer
400,000 +57.5%
0.34
US$137,000 		400,000 +57.5% 0.34 US$137,000
2023-12-19 2023-12-19 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
13,680 +136.8%
0.32
US$4,378 		13,680 +136.8% 0.32 US$4,378
2023-12-19 2023-12-18 B Purchase
3.8
Puhlmann Markus

Chief Medical Officer

Officer
60,419 +9.5%
0.26
US$15,461 		60,419 +9.5% 0.26 US$15,461
2023-12-19 2023-12-18 B Purchase
4.1
Williamson Robert F III
Non-Executive Director
10,000 +inf%
0.26
US$2,600 		10,000 +inf% 0.26 US$2,600
2023-12-19 2023-12-18 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
125,000 +65.2%
0.26
US$32,338 		125,000 +65.2% 0.26 US$32,338
2023-12-19 2023-12-15 B Purchase
3.8
Puhlmann Markus

Chief Medical Officer

Officer
135,006 +27.0%
0.27
US$36,276 		135,006 +27.0% 0.27 US$36,276
2023-12-18 2023-12-15 B Purchase
4.0
Woods Lori A
Non-Executive Director
152,962 +11.2%
0.27
US$41,284 		152,962 +11.2% 0.27 US$41,284
2023-12-18 2023-12-14 B Purchase
4.0
Woods Lori A
Non-Executive Director
32,238 +2.4%
0.27
US$8,704 		32,238 +2.4% 0.27 US$8,704
2022-12-05 2022-12-05 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
32,200 +20.2%
0.38
US$12,236 		32,200 +20.2% 0.38 US$12,236
2022-12-05 2022-12-01 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
53,204 +50.0%
0.38
US$20,265 		53,204 +50.0% 0.38 US$20,265
2022-11-17 2022-11-15 B Purchase
4.0
Woods Lori A

CEO

Executive Director
100,000 +9.6%
0.34
US$33,540 		100,000 +9.6% 0.34 US$33,540
2022-06-09 2022-06-09 B Purchase
3.5
Austin Mark John

VP Finance/Prin Fin&Acct Offic

Officer
13,800 +34.3%
0.29
US$3,959 		13,800 +34.3% 0.29 US$3,959
2022-06-09 2022-06-08 B Purchase
3.5
Austin Mark John

VP Finance/Prin Fin&Acct Offic

Officer
5,000 +14.2%
0.29
US$1,425 		5,000 +14.2% 0.29 US$1,425
2022-06-09 2022-06-08 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
25,675 +31.8%
0.29
US$7,443 		25,675 +31.8% 0.29 US$7,443
2022-06-09 2022-06-07 B Purchase
4.0
Woods Lori A

CEO

Executive Director
75,000 +7.7%
0.30
US$22,230 		75,000 +7.7% 0.30 US$22,230
2022-06-09 2022-06-07 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
13,325 +19.8%
0.28
US$3,718 		13,325 +19.8% 0.28 US$3,718
2020-12-02 2020-11-30 B Purchase
4.0
Woods Lori A

CEO

Executive Director
68,000 +12.5%
0.38
US$25,534 		68,000 +12.5% 0.38 US$25,534
2020-10-28 2020-10-22 B Purchase
3.8
Hunt Jonathan Robert

Chief Financial Officer

Officer
67,306 +inf%
0.52
US$34,999 		67,306 +inf% 0.52 US$34,999
2020-10-28 2020-10-22 B Purchase
McCormick Michael W
Non-Executive Director
19,230 +87.4%
0.52
US$10,000 		19,230 +87.4% 0.52 US$10,000
2020-10-28 2020-10-22 B Purchase
4.0
Woods Lori A

CEO

Executive Director
48,076 +inf%
0.52
US$25,000 		48,076 +inf% 0.52 US$25,000
2020-10-28 2020-10-22 B Purchase
Cavanagh William

Chief R&D Officer

Officer
7,692 +38.5%
0.52
US$4,000 		7,692 +38.5% 0.52 US$4,000
2020-10-28 2020-10-22 B Purchase
Hoffmann Alan
Non-Executive Director
19,230 +inf%
0.52
US$10,000 		19,230 +inf% 0.52 US$10,000
2020-10-28 2020-10-22 B Purchase
3.5
Austin Mark John

Controller/Prin Fin&Acct Offic

Officer
19,230 +120.2%
0.52
US$10,000 		19,230 +120.2% 0.52 US$10,000
2020-10-28 2020-10-22 B Purchase
Vitale Philip J
Non-Executive Director
20,000 +18.2%
0.52
US$10,400 		20,000 +18.2% 0.52 US$10,400
2020-10-28 2020-10-22 B Purchase
Krachon Michael

EVP of Sales & Marketing

Officer
28,844 +52.4%
0.52
US$14,999 		28,844 +52.4% 0.52 US$14,999
2019-11-21 2019-11-20 B Purchase Krachon Michael

VP of Sales & Marketing

Officer
50,000 +inf%
0.39
US$19,495 		50,000 +inf% 0.39 US$19,495
2019-11-19 2019-11-15 B Purchase Cavanagh William

Chief R&D Officer

Officer
10,000 +100.0%
0.39
US$3,900 		10,000 +100.0% 0.39 US$3,900
2019-11-19 2019-11-15 B Purchase Woods Lori A

CEO

Executive Director
25,000 +9.8%
0.39
US$9,745 		25,000 +9.8% 0.39 US$9,745
Explore more

More insider trading research around Perspective Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America